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Introduction: Over the past several years, Clostridioides difficile infection (CDI) incidence has 
been rising. The primary risk factor for CDI is antibiotic use. Many studies indicate that 
penicillin drugs are among the low-risk antibiotic classes associated with CDI whereas 
cephalosporin drugs are among the high-risk antibiotic classes. However, there is variation in 
studies evaluating the healthcare-associated CDI (HA-CDI) risk associated with antibiotics 
within a class and limited data comparing the use of penicillin versus cephalosporin drugs. 
Methods: An observational cohort study was performed using patient data from BH and YNHH. 
Minitab (Version 18) was used to perform survival analysis and multivariate logistic regression. 
Charlson comorbidity index scores were utilized to control and adjust for underlying 
comorbidities, and adjusted odds ratios were calculated using backwards elimination. 
Results: Data collected from a 5-year period between February 1, 2013 and June 1, 2018 
revealed that piperacillin/tazobactam exposure at YNHH was associated with a higher CDI risk 
than penicillin exposure (p = 0.016). Additional covariates included H2A use (OR = 0.497, p = 
0.027), Charlson comorbidity index scores (OR = 0.848, p = 0.025), and longer duration of 
hospital admission (OR = 1.038, p < 0.001). 
Discussion: The findings in the YNHH cohort may justify an investigation into de-escalation of 
piperacillin/tazobactam empiric therapy intended for suspected infection caused by Gram-
negative bacteria. Further study is needed to better address the association between the covariates 
and CDI risk in the BH cohort. Next steps may include an aggregate analysis of CDI risk 
between penicillin drugs and cephalosporin drugs along with a closer exploration of the facility 
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Table 1: BH Demographics 
 




Table 2: BH Piperacillin/Tazobactam Multivariate Regression Model 
 
Table 2: The multivariate logistic regression model for the BH piperacillin/tazobactam group. Statistical significance 
is determined by a p-value of < 0.05. The superscript (1) indicates an unadjusted model, whereas the superscript (2) 











BH Piperacillin/tazobactam (N = 946) BH Cefepime (N = 2720) P-value
Patient Demographics
     Age, mean (SD) 64.8 (19.0) 69.4 (17.7) < 0.001
     Male, n (%) 510 (53.9) 1354 (49.8) 0.029
     Charlson Comorbidity Index Score, mean (SD) 2.4 (2.4) 2.8 (2.4) < 0.001
     Days of Hospital Admission, mean (SD) 14.0 (11.2) 10.8 (9.1) < 0.001
Patient Characteristics
     Days of Therapy, mean (SD) 4.5 (2.0) 4.9 (2.3) < 0.001
     High-Risk Antibiotic Therapy, n (%) 613 (64.8) 1674 (61.5) NS
     Proton-Pump Inhibitor Therapy, n (%) 442 (46.7) 1583 (58.2) < 0.001
     Histamine-2-Receptor Antagonist Therapy, n (%) 469 (49.6) 1947 (71.6) < 0.001
C. difficile  Assay
Tested, n (%) 122 (12.9) 157 (5.8) < 0.001
     Positive, n (%) 12 (1.3) 25 (0.9) NS
     Negative, n (%) 110 (11.6) 132 (4.9) < 0.001













High-Risk Antibiotic Therapy 6.636 (0.815, 49.652) 0.024 6.066 (0.780, 47.190) 0.024
PPI Therapy 0.542 (0.161, 1.824) 0.31 - - -
H2A Therapy 1.548 (0.485, 4.943) 0.457 - - -
Male 0.565 (0.177, 1.804) 0.331 - - -
Charlson Comorbidity Index Score 1.224 (1.023, 1.463) 0.043 1.247    (1.048, 1.484) 0.024
Age 1.003 (0.969, 1.038) 0.853 - - -
Days of Hospital Admission 1.028 (0.993, 1.065) 0.161 - - -
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Table 3: BH Cefepime Multivariate Regression Model 
 
Table 3: The multivariate logistic regression model for the BH cefepime group. Statistical significance is determined 
by a p-value of < 0.05. The superscript (1) indicates an unadjusted model, whereas the superscript (2) indicates the 




Table 4: YNHH Demographics 
 



























High-Risk Antibiotic Therapy 2.029 (0.807, 5.105) 0.113 - - -
PPI Therapy 1.47 (0.631, 3.426) 0.362 - - -
H2A Therapy 0.426 (0.193, 0.940) 0.038 0.426 (0.194, 0.938) 0.038
Male 0.805 (0.363, 1.782) 0.591 - - -
Charlson Comorbidity Index Score 1.074 (0.919, 1.256) 0.376 - - -
Age 1.018 (0.991, 1.044) 0.178 - - -
Days of Hospital Admission 1.040 (1.012, 1.069) 0.015 1.040 (1.013, 1.068) 0.012
YNHH Piperacillin/tazobactam (N = 5239) YNHH Ceftazidime (N = 3004) P-value
Patient Demographics
     Age, mean (SD) 63.5 (17.6) 64.3 (17.2) NS
     Male, n (%) 3074 (58.7) 1600 (53.3) < 0.001
     Charlson Comorbidity Index Score, mean (SD) 2.8 (2.4) 2.7 (2.3) NS
     Days of Hospital Admission, mean (%) 14.5 (13.4) 14.9 (13.7) NS
Patient Characteristics
     Days of Therapy, mean (SD) 4.2 (2.0) 4.5 (2.2) < 0.001
     High-Risk Antibiotic Therapy, n (%) 3194 (61.0) 1753 (58.3) 0.020
     Proton-Pump Inhibitor Therapy, n (%) 2460 (47.0) 1324 (44.1) 0.011
     Histamine-2-Receptor Antagonist Therapy, n (%) 3071 (58.9) 1827 (60.8) NS
C. difficile  Assay 
% Tested 683 (13.0) 165 (5.5) < 0.001
     Positive, n (%) 41 (0.8) 12 (0.4) 0.036
     Negative, n (%) 642 (12.3) 153 (5.1) < 0.001




Table 5: YNHH Piperacillin/Tazobactam Multivariate Regression Model 
 
Table 5: The multivariate logistic regression model for the YNHH piperacillin/tazobactam group. Statistical 
significance is determined by a p-value of < 0.05. The superscript (1) indicates an unadjusted model, whereas the 




Table 6: YNHH Ceftazidime Multivariate Regression Model 
 
Table 6: The multivariate logistic regression model for the YNHH ceftazidime group. Statistical significance is 
determined by a p-value of < 0.05. The superscript (1) indicates an unadjusted model, whereas the superscript (2) 





















High-Risk Antibiotic Therapy 1.253 (0.654, 2.402) 0.492 - - -
PPI Therapy 0.789 (0.421, 1.476) 0.455 - - -
H2A Therapy 0.499 (0.267, 0.931) 0.027 0.497 (0.267, 0.928) 0.027
Male 1.075 (0.572, 2.020) 0.823 - - -
Charlson Comorbidity Index Score 0.829 (0.706, 0.973) 0.014 0.848 (0.727, 0.988) 0.025
Age 1.012 (0.994, 1.030) 0.198 - - -













High-Risk Antibiotic Therapy 1.555 (0.465, 5.203) 0.464 - - -
PPI Therapy 0.246 (0.054, 1.129) 0.039 0.253 (0.055, 1.155) 0.043
H2A Therapy 0.326 (0.098, 1.086) 0.058 - - -
Male 0.879 (0.282, 2.739) 0.825 - - -
Charlson Comorbidity Index Score 1.156 (0.913, 1.463) 0.245 - - -
Age 1.041 (0.997, 1.087) 0.053 1.043 (1.000, 1.088) 0.001





Figure 1: Kaplan-Meier curve comparing the CDI risk between the BH piperacillin/tazobactam and BH cefepime 
groups. The X-axis represents the days of therapy with each respective antibiotic, whereas the Y-axis represents the 






Figure 2: Kaplan-Meier curve comparing the CDI risk between the YNHH piperacillin/tazobactam and YNHH 
ceftazidime groups. The X-axis represents the days of therapy with each respective antibiotic, whereas the Y-axis 
















 Clostridioides difficile is a gram-positive, anaerobic, and spore-forming bacterium that 
causes inflammation of the colon, otherwise known as colitis.1 It is the leading cause of 
pseudomembranous colitis and antibiotic-associated diarrhea among hospitalized patients.2 
Symptoms characteristic of Clostridioides difficile infection (CDI) include abdominal cramping, 
varying degrees of diarrhea severity, dehydration, weight loss, and fever.3 Following ingestion, 
the acid-resistant C. difficile spores bypass the stomach’s acid barrier and are able to germinate 
into vegetative cells.1 The vegetative cells secrete two primary virulent factors: C. difficile Toxin 
A (TcdA) and C. difficile Toxin B (TcdB).1 TcdA, one of the largest bacterial toxins, is a protein 
enterotoxin that assembles to form pores in cell membranes.2 TcdB is a cytotoxin that causes a 
disruption in signal transduction pathways to initiate apoptosis.2 Together, TcdA and TcdB act to 
disrupt the intestinal mucosa and are directly responsible for causing characteristic CDI 
manifestations including pseudomembranous colitis.2 The primary mode of transmission for CDI 
is the fecal-oral route in which the bacterial spores may contaminate various surfaces, devices, or 
additional materials for long durations of time.4 These spores are mainly transmitted through the 
hands of healthcare personnel following contact with a contaminated surface.4  
CDI is divided into three main laboratory classifications: community-onset CDI (CO-
CDI), hospital-onset CDI (HO-CDI), and community-onset healthcare facility-associated CDI 
(CO-HCFA).5 CO-CDI is defined as the collection of a stool specimen which tested positive for 
C. difficile ≤ 3 days within hospital admission, and HO-CDI is defined as collection of a stool 
specimen which tested positive for C. difficile > 3 days after hospital admission.5 CO-HCFA is 
defined as the collection of a stool specimen which tested positive for C. difficile ≤ 4 weeks after 
hospital discharge.5 Some literature shows that many cases of hospital-associated CDI (HA-CDI) 
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are community-onset.6,7 In cases that are community-onset and healthcare-associated, antibiotic 
exposure in the hospital setting is likely to trigger infection. As a result, the link between 
community-associated CDI (CA-CDI) and HA-CDI has become a key focus point in measuring 
CDI trends in recent years. 
Over the past several years, there has been a rise in incidence, prevalence, as well as 
corresponding morbidity and mortality associated with CDI. 8 In many areas of the United States, 
C. difficile has overtaken methicillin-resistant Staphylococcus aureus (MRSA) as the chief 
pathogen causing healthcare-associated infections (HAIs).8,9 A 2011 study from the Centers for 
Disease Control and Prevention (CDC) estimated there to be 493,000 CDI cases a year, out of 
which 83,000 were recurrent infections and 29,300 cases resulted in death.8 It has also been 
reported that out of the 493,000 CDI cases, nearly a quarter (24.2%) were classified as HO-
CDI.10 Between 1996 and 2000, the reported CDI incidence in US acute-care facilities was 30-40 
discharges per 100,000 acute-care hospitalizations.11,12 This incidence doubled in 2003 to 60 
discharges per 100,000 acute-care hospitalizations.11 Additionally, the number of hospital stays 
with a CDI discharge diagnosis saw a 2.5-fold increase between the years 2000 and 2008.11 The 
number of hospital stays with a principal CDI diagnosis1,13 saw a 3.5-fold increase during the 
same time period.11 CDI had comprised approximately 1% of all US hospital admissions in 
2009.11 Moreover, CDI-associated mortality has seen a steady increase over time. A 9-fold 
increase in the number of deaths with CDI as the primary cause has been observed between 1999 
and 2008.11 Other studies have further stratified the data for CDI-associated mortality by 
examining trends concerning gastroenteritis-associated deaths. CDI mortality experienced a 5-
                                                          
1 Principal diagnosis – the condition established to be chiefly responsible for the patient’s 
admission to the hospital. 
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fold increase between 1999 and 2007; C. difficile was identified as the main contributor to 
gastroenteritis-associated deaths in US acute-care facilities.11  
CDI cases incur excess costs of $4.8 billion in acute care facilities.14 CDI incurs higher 
costs by extending the length of hospital admission and increasing the risk for further adverse 
events such as other HAIs. Some studies show that the average hospital length of admission for 
secondary CDI diagnoses2 was more than twice as long than for principal CDI diagnoses.11,13 
Secondary CDI diagnoses incurred a cost more than three times higher than that of principal CDI 
diagnoses.11 Three primary hypotheses have been proposed to explain the rising incidence, 
prevalence, morbidity, and mortality of CDI: inadequate environmental cleaning practices, over 
and under identification of cases, and permissive indications for initiating antibiotic therapy.15,16 
Many studies pinpoint antibiotic prescribing habits as the primary contributor to the rising CDI 
rates over time.17,18,19  
Commensal flora in the human gut play an important role in warding off pathogenic 
colonization or infection. Secondary bile acids, metabolized by commensal gut bacteria, will in 
many cases prevent germination of C. difficile spores into vegetative cells.20 The commensal 
flora typically produce bacteriocins, neutralize toxins, and outcompete pathogens for consuming 
available nutrients.20 These native functions are able to prevent vegetative cells from attaching to 
and colonizing the gut epithelium.20 These native functions additionally inhibit production of 
TcdA and TcdB.20 Antibiotic therapy alters the commensal flora in the gut, thus compromising 
the integrity of the physical and biochemical barriers in place that prevent CDI.1,21 Though the 
specifics of the gut microbiome alterations are not fully understood, several studies propose that 
                                                          
2 Secondary diagnosis – concomitant conditions that coexist at the time of admission or that 
develop during the stay. 
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there is a decrease in commensal flora, thus weakening the physical and biochemical barriers 
against CDI.22,23,24 Due to the change in the commensal flora composition, antibiotic use poses a 
significant risk for CDI.  
CDI risks by antibiotic class vary across studies. In most studies, low risk antibiotics 
include penicillins, macrolides, and tetracyclines.25,26 A meta-analysis performed by Brown, et. 
al. depicted CDI risks stratified by antibiotic class by identifying trends across various studies.25 
HA-CDI studies were excluded as well as studies restricted to only oncology or HIV patients. 
The meta-analysis aimed to pool together studies showing incident CDI dependent upon 
antibiotic exposure. CDI risks ranged from an odds ratio of 1.72 to 6.50 for penicillins, an odds 
ratio of 2.19 to 4.01 for macrolides, and an odds ratio of 0.90 to 1.10 for tetracyclines.25 Another 
meta-analysis performed by Deshpande, et. al. followed a similar method.26 The group focused 
on community-associated CDI and also sought to identify antibiotic exposure risk factors 
associated with incident CDI. CDI risks ranged from an odds ratio of 1.89 to 5.57 for penicillins, 
an odds ratio of 1.91 to 3.39 for macrolides, and an odds ratio of 0.57 to 1.45 for tetracyclines.26 
A common theme across both meta-analyses was the relatively high degree of variation of CDI 
risk associated with penicillin antibiotics. 
Among the penicillin class of antibiotics, studies with piperacillin/tazobactam show 
inconsistent data regarding its association with CDI risk.27,28,29 A study conducted by Shah, et. al. 
examined HA-CDI risk with individual antibiotics within an antibiotic class.27 Since existing 
literature depicts a relatively large degree of variation in CDI risk from penicillin exposure, 
inpatient surgery patients were evaluated for incident CDI. Patients with diarrhea were 
retrospectively examined for previous antibiotic exposure. The odds ratio for 
piperacillin/tazobactam ranged from 1.32 to 4.50, once again showing significant variation 
14 
 
among individual patients.27 Another cohort study performed by Bow, et. al. looked at oncology 
and transplant patients with respect to C. difficile-associated diarrhea incidence.29 In a cohort of 
265 patients receiving piperacillin/tazobactam therapy, approximately 2.3% developed CDI.29 
Another point of comparison in the study was with an individual antibiotic from a known high-
risk antibiotic class. 
In most studies, high-risk antibiotics are comprised of cephalosporins, clindamycin, 
carbapenems, and fluoroquinolones.25,26,30 The Brown, et. al. meta-analysis showed CDI risks 
ranging from an odds ratio of 2.20 to 14.90 for cephalosporins and carbapenems, an odds ratio of 
6.64 to 31.80 for clindamycin, and an odds ratio of 1.31 to 9.39 for fluoroquinolones.25 The 
Deshpande, et. al. meta-analysis showed similar CDI risks ranging from an odds ratio of 1.60 to 
12.50 for cephalosporins, an odds ratio of 8.50 to 49.09 for clindamycin, and an odds ratio of 
4.38 to 7.28 for fluoroquinolones.26 While the documented CDI risk associated with clindamycin 
use has a high degree of variation, the average risk remains high across multiple studies. 
Although there is a great deal of variation in CDI risk associated with cephalosporin exposure, its 
odds ratio is much lower when compared to that of other known high-risk antibiotics.  
Studies show varying CDI risk associated with ceftazidime and cefepime, third and 
fourth-generation cephalosporins, respectively.27,28,29 There are very few studies depicting CDI 
risk associated with ceftazidime exposure alone, instead grouping ceftazidime in a category of 
third and fourth-generation cephalosporins. A study conducted by Shah, et. al. documented an 
odds ratio ranging from 1.72 to 19.1 for cefepime associated CDI risk.27 The Muldoon, et. al. 
group has shown an average odds ratio of 2.10 of CDI risk associated with cefepime exposure.28 
The data shows a large degree of variation despite the fact that cephalosporins as a class are 
typically associated with a high CDI risk. A cohort study carried out by Bow, et. al. shows that 
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among a cohort of 263 patients receiving cefepime therapy, 6.8% developed CDI.29 Although 
some studies show a higher CDI risk with cephalosporins, the variation observed across 
individual patients brings a significant degree of uncertainty into the equation, especially given 
the multitude of additional CDI risk factors present in an acute-care setting.  
Piperacillin/tazobactam, ceftazidime, and cefepime are β-lactam anti-pseudomonal 
agents. Piperacillin/tazobactam possesses coverage against Gram-positive, Gram-negative, and 
anaerobic bacteria.31,32 Ceftazidime possesses coverage against Gram-negative bacteria; its 
primary limitation relative to piperacillin/tazobactam is limited Gram-positive and anaerobic 
coverage.31,32 Cefepime possesses coverage against both Gram-positive and Gram-negative 
bacteria, providing some advantages over ceftazidime.31,32 Cefepime has limited activity against 
anaerobic bacteria.31 Depending on the clinical situation, this poses a limitation relative to 
piperacillin/tazobactam. 
In order to evaluate CDI risk factors associated with piperacillin/tazobactam, cefepime, 
and ceftazidime, the CDI risk associated with their empiric use is evaluated in the two largest 
hospitals in the Yale New Haven Health System: Bridgeport Hospital (BH) and Yale New Haven 
Hospital (YNHH). Based on antibiograms and provider preference, cefepime is the preferred 
broad-spectrum antibiotic for empiric use at BH, and piperacillin/tazobactam is the preferred 
broad-spectrum antibiotic for empiric use at YNHH. Piperacillin/tazobactam is additionally on 
the formulary at BH, and ceftazidime is on the formulary at YNHH.  
A formulary is defined as a continually updated list of medications and related 
information, representing the clinical judgment of pharmacists, physicians, and other experts in 
the diagnosis and/or treatment of disease and promotion of health.33,34 It makes up one element 
of a broader formulary system, which includes medication use policies, a pharmacy and 
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therapeutics committee, medication use evaluation, and formulary management.33,34 The 
formulary system serves the purpose of evaluating medications on an ongoing basis for inclusion 
and exclusion, establishing guidelines for optimal medication use, developing policies and 
procedures for prescribing, dispensing, and administering medications.33 The delivery of changes 
to the formulary system fall under the jurisdiction of the pharmacy and therapeutics committee. 
Formulary access is categorized as either open or closed. An open formulary has no limit 
or restriction on medications, whereas a closed formulary has a limited list of available 
medications.33 When considering the use of several antibiotics, formulary restrictions are often 
placed to better optimize medication management. Some data suggests that restricting 
formularies may impose higher healthcare costs by increasing utilization of physician visits and 
hospitalizations.33 While the data is the subject of controversy, the impact on healthcare costs is a 
notable factor in driving changes to the formulary. In order to change a formulary, a member or 
members of the pharmacy or medical staff must submit a request for formulary addition or 
deletion.33 The submission requests are comprised of 1) the agent to be considered for addition or 
deletion, 2) the rationale for the request, and 3) alternative agents currently on the formulary.33 
There are several patient care and financial considerations that play a role in initiating a 
formulary change. Patient care considerations primarily include questions regarding medication 
safety and efficacy, whereas financial considerations mainly include questions regarding the cost 
of the drug as well as costs associated with stocking the drug that include handling, drug 
outdates, and shelf space.33  
In theory, the existing formularies at BH and YNHH should have no significant 
difference in the risk of acquiring CDI between penicillin (piperacillin/tazobactam) and 
cephalosporin drugs (cefepime and ceftazidime). Based on current literature, there is 
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hypothesized to be a significant difference in CDI risk between empiric therapy of the 
aforementioned penicillin and cephalosporin drugs. The study’s primary goal is to evaluate the 
comparative risk for HA-CDI by comparing the uses of penicillin and cephalosporin drugs. The 
findings may unveil an increased, significant HA-CDI risk associated with a particular antibiotic 
that is not reported in existing literature. If an increased HA-CDI risk is observed, it may 
potentially guide efforts for antibiotic stewardship, advise formulary decisions, and decrease 
overall patient risk of CDI. Several factors are considered in a formulary shift including a 
significant difference in CDI risk, any known significant difference in other multidrug-resistant 
infection risk, and healthcare costs. Additionally, the potential findings may prompt peer 
hospitals to explore similar studies concerning empiric antibiotic use. As HA-CDI grows in 
prevalence, clinical research is paramount to optimize antibiotic stewardship. Although extensive 
literature exists that documents CDI risk associated with antibiotics, few studies include a risk 
stratification by antibiotic class. Even fewer studies exist that break down members of each 
antibiotic class to account for variation within an antibiotic class. This study aims to provide 
more insight into the association between HA-CDI and individual drugs within antibiotic classes 











Study Design and Participants 
An observational cohort study was conducted at the Yale New Haven Health System 
(YNHHS) to include patient data at BH and YNHH from February 1, 2013 to June 1, 2018. This 
timeline sought to encompass documented patient data since the inception of Epic (© 2019 Epic 
Systems Corporation, Verona, WI) – the electronic medical record utilized at both hospitals. The 
study reviewed medical records from BH (Bridgeport, CT) a 357-bed academic medical center as 
well as from YNHH (New Haven, CT), a 1,541-bed tertiary care academic medical center.  
Patients who had received ≥ 3 days of piperacillin/tazobactam, cefepime, or ceftazidime 
therapy were included.19 Patients in each cohort group were included provided that they were 
only admitted to the hospital of concern (i.e. patients with separate admissions at BH and YNHH 
were excluded regardless of time gap). Patients meeting the antibiotic exposure definition were 
included provided that they only received the antibiotic therapy of concern (i.e. a patient 
receiving any combination of piperacillin/tazobactam, cefepime, or ceftazidime therapy was 
excluded). In order to address patients with multiple admissions over a period of time, only the 
first hospital admission meeting the inclusion criteria was included as a data point along with the 
rest of the corresponding data points.  
Numerous hospital units were excluded: oncology (surgical, medical, hematology), 
transplant (stem cell, solid organ), and pediatric (oncology, transplant). These exclusions were 
made since BH does not provide oncology care for patients with acute hematological 
malignancies or care for stem cell or solid organ transplants. The exclusions were made to 
standardize the patient populations between both hospitals. As the excluded units care for 
severely ill and immunocompromised patients, their exclusion from the data set was also to 
19 
 
ensure the two cohorts are directly comparable. Patients under the age of 18, patients who had 
been hospitalized for < 2 days, patients who had been hospitalized for ≥ 120 days, and HIV 
positive patients with a CD4 T-cell count of < 200 were excluded.  
The Institutional Review Boards (IRB) of both Bridgeport Hospital and Yale University 
deemed the study as exempt from IRB approval, designating the study as a quality improvement 
project. 
Definitions 
A standard dose of piperacillin/tazobactam is defined as 4.5 g every 6 hours.31 A standard 
dose of ceftazidime and cefepime are defined as 2 g every 8-12 hours.31 Exposure to 
piperacillin/tazobactam, ceftazidime, or cefepime therapy is defined as ≥ 3 contiguous days of 
treatment. A positive HA-CDI diagnosis is defined as one made ≥ 48 hours after admission in 
accordance with the CDC NHSN LabID and each hospital’s C. difficile assay (see Appendix 1 
and 2).35 
Exposure to high-risk antibiotic therapy is defined as ≥ 3 contiguous days of treatment 
with a combination or standalone of the following antibiotics on both hospital formularies: 
ciprofloxacin, moxifloxacin, clindamycin, ertapenem, or meropenem. Other antibiotics 
administered within the documented high-risk antibiotic classes were not included. Exposure to 
proton-pump inhibitor (PPI) therapy is defined as ≥ 3 contiguous days of treatment with either of 
the following agents on both hospital formularies: lansoprazole or pantoprazole. Exposure to 
histamine-2-receptor antagonist (H2A) therapy is defined as ≥ 3 contiguous days of treatment 






Patient data from the electronic health record over the course of the five-year study 
period was extracted by the Yale Joint Data Analytics Team (JDAT), a team handling clinical 
and research analytics across the Yale New Haven Health System and the Yale School of 
Medicine. Regarding additional data points, CD4 T-cell counts for HIV patients and Charlson 
comorbidity index scores for the date of discharge were obtained using ICD-10 codes. 
Demographic data for each patient included 1) age at the first hospital admission, 2) sex 
(male), 3) name of hospital (BH or YNHH), 4) length of stay (calculated by finding difference 
between date of admission and date of discharge), 5) high-risk antibiotic therapy (binary), 6) PPI 
therapy (binary), 7) H2A therapy (binary), 8) days of piperacillin/tazobactam, cefepime, or 
ceftazidime therapy, and 9) Charlson comorbidity index scores upon patient discharge. The 
electronic Charlson comorbidity index was generated by YNHHS and utilized based on the 
original and updated indexes.36,37 The primary exposure variables included days of 
piperacillin/tazobactam therapy, days of cefepime therapy, and days of ceftazidime therapy. The 
primary outcome variable assessed was the diagnosis of HA-CDI. 
Statistical Analysis 
 Demographic data was compiled using Microsoft Excel (Office 16) and segregated by 
individual group at BH and YNHH. Regarding CDI outcomes, the null (not tested) and negative 
tests were grouped together for subsequent analysis. As the chief measure of the study was the 
risk of acquiring CDI dependent on antibiotic exposure, null and negative results were grouped 
as “not acquiring” CDI. Another justification for performing the groupings in this manner was 
due to feedback from attending physicians and hospital epidemiologists in terms of determining 
the appropriateness for testing. Microsoft Excel was also used to determine the distributions of 
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the continuous covariates to guide further analysis. Chi-squared tests were used to determine 
statistical significance between the covariates in the demographic tables.  
Survival analysis was performed using Minitab Version 18 (© 2019 Minitab, LLC, State 
College, PA) to measure the proportion of individuals with disease survival by days of antibiotic 
therapy. Survival analysis was performed for both BH and YNHH, directly comparing each 
cohort group with regards to CDI risk. The survival plots censored patients at hospital discharge 
after which they could no longer be closely observed for CDI risk.  
The multivariate logistic regression models were constructed using Minitab to measure 
the confounding association between the proportion of individuals with a positive CDI diagnosis 
and the multiple confounding variables listed. The regression models were separated by binary 
and continuous confounding variables. The binary covariates consisted of high-risk antibiotic 
therapy, PPI therapy, H2A therapy, and the male sex. The continuous covariates consisted of 
Charlson comorbidity index scores, age, and length of hospital admission. Similar to the logic in 
the survival analysis, these models were separated by each hospital to compare both cohorts. 
These models were divided into two main areas: one unadjusted model and one adjusted mode 
using the method of backwards elimination. Statistical significance was determined by using a p-










In the 5-year study period, there were a total of 11,909 eligible patients in the total study 
population. There were 3,666 eligible patients included from BH. 946 were in the 
piperacillin/tazobactam group, and 2,720 were in the cefepime group (Table 1). The BH 
cefepime group had a higher average age upon admission than the BH piperacillin/tazobactam 
group, and the ages for both groups were normally distributed. The BH piperacillin/tazobactam 
group (53.9%) had a slightly higher proportion of male patients than the BH cefepime group 
(49.8%) (p = 0.029). The BH cefepime group (58.2%) had more frequent PPI use than the BH 
piperacillin/tazobactam group (46.7%) (p < 0.001). The BH cefepime group (71.6%) had more 
frequent H2A use than the BH piperacillin/tazobactam group as well (49.6%) (p < 0.001). 
Although the BH piperacillin/tazobactam group had a higher average duration of hospital 
admission than the BH cefepime group, both groups had similar Charlson comorbidity index 
scores. Both the average duration of hospital admission and Charlson comorbidity index scores 
were not normally distributed, in which most values fell below the reported means in Table 1. 
The BH piperacillin/tazobactam group (12.9%) was tested for CDI more frequently than the BH 
cefepime group (5.8%) (p < 0.001). The rate of positive C. difficile tests did not differ between 
both groups. 
According to survival analysis, the BH cefepime group displayed a slightly higher risk 
for incident CDI (Figure 1). The curve for the BH cefepime group begins to sharply shift 
downwards around the 13-14 days of therapy mark (Figure 1). However, this discrepancy was 
not supported by statistical significance (p = 0.127).  
The CDI risk for each group was further broken down to account for potential 
confounders that may explain the observed discrepancies. In the BH piperacillin/tazobactam 
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group, high-risk antibiotic use and patients’ Charlson comorbidity index scores (higher) were 
associated with a higher CDI risk in the adjusted model using backwards elimination (OR = 
6.066 and OR = 1.247, respectively) (Table 2). In the adjusted model for the BH cefepime group, 
H2A use was associated with a lower CDI risk, in which the odds ratio was 0.426 (p = 0.038). 
Longer duration of hospital admission was associated with a higher CDI risk, in which the odds 
ratio was 1.040 (p = 0.012) (Table 3). 
There were 8,243 eligible patients included from YNHH. 5,239 were in the 
piperacillin/tazobactam group, and 3,004 were in the ceftazidime group (Table 4). The YNHH 
piperacillin/tazobactam and YNHH ceftazidime groups had similar average ages upon 
admission, and the ages were normally distributed. The YNHH piperacillin/tazobactam group 
(58.7%) had a higher proportion of male patients than the YNHH ceftazidime group (53.3%) (p 
< 0.001). The YNHH piperacillin/tazobactam group (61.0%) had more frequent high-risk 
antibiotic use than the YNHH ceftazidime group (58.3%) (p = 0.020). The YNHH 
piperacillin/tazobactam group (47.0%) had more frequent PPI use than the YNHH ceftazidime 
group (44.1%) (p = 0.011). The average duration of hospital admission and Charlson 
comorbidity index scores were similar for both groups. Both data points were not normally 
distributed in that most values fell below the means reported in Table 4. The YNHH 
piperacillin/tazobactam group was tested for C. difficile more frequently than the YNHH 
ceftazidime group (p < 0.001). The YNHH piperacillin/tazobactam group (0.8%) also had a 
slightly higher rate of positive C. difficile tests than the YNHH ceftazidime group (0.4%) (p = 
0.036). 
According to survival analysis, the YNHH ceftazidime group was associated with a 
higher CDI risk than the YNHH piperacillin/tazobactam group (p = 0.016) (Figure 2). At the 11-
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12 mark of days of therapy, the curve for the YNHH piperacillin/tazobactam group began to shift 
downwards below that of the ceftazidime group.  
To further explore the observed discrepancies, the CDI risk for each group was broken 
down to account for possible confounders. In the YNHH piperacillin/tazobactam group, H2A use 
and patients’ Charlson comorbidity index scores (lower) were found to be associated with a 
lower CDI risk in the adjusted model by utilizing the backwards elimination method (OR = 
0.497 and OR = 0.848, respectively) (Table 5). A longer duration of hospital admission was 
associated with a higher CDI risk in the adjusted model (OR = 1.038). In the YNHH ceftazidime 
group, a patient’s age (higher) and duration of hospital admission (longer) were found to be 
associated with an increased CDI risk in the adjusted model (OR = 1.043 and OR = 1.046, 
respectively) (Table 6). PPI use in the YNHH ceftazidime group was shown to be associated 














In the BH cohort, there was no significant difference in CDI risk between 
piperacillin/tazobactam and cefepime as displayed in Figure 1. As a result, this fails to reject the 
null hypothesis of the CDI risk being the same between penicillin and cephalosporin drugs. 
 As illustrated in Table 2, patients in the BH piperacillin/tazobactam group receiving high-
risk antibiotic therapy (in addition to piperacillin/tazobactam therapy) had 6.066 times the odds 
of developing CDI than patients not receiving high-risk antibiotic therapy. These odds align well 
with existing literature, which have displayed an extremely wide range of odds ratios from 1.31 
to 49.09.25,26,38 Patients in the BH piperacillin/tazobactam group with a higher Charlson 
comorbidity index score were shown to have slightly higher odds of developing CDI than 
patients with a lower score. Current literature postulates that certain patients such as those with 
CDI typically have slightly higher Charlson comorbidity index scores than those without CDI, in 
which odds ratios range from 1.150 to 1.265.39,40,41  
Table 3 indicates that patients in the BH cefepime group with a longer duration of 
hospital admission had slightly higher odds of developing CDI than those with a shorter length 
of stay. A longer length of stay is hypothesized to provide a prolonged medium for a patient to 
be exposed to C. difficile. Events such as requiring antibiotic therapy due to developing an 
infection or being in close proximity to other patients with C. difficile may contribute to the link 
between longer length of stay and CDI risk.  
Table 3 showed that patients in the cefepime group receiving H2A therapy (in addition to 
cefepime therapy) had 0.426 times the odds of developing CDI than those who did not. H2As are 
prescribed to patients who exhibit symptoms of conditions such as gastroesophageal reflux 
disease (GERD), peptic ulcers, or Helicobacter pylori infection.42 H2A use is intended for gastric 
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acid suppression, though this is hypothesized to introduce favorable conditions for C. difficile 
proliferation.43 Several studies demonstrate that H2A is a risk factor for CDI, in which the odds 
ratios range from 1.06 to 3.00.43 However, other studies have shown inconsistent data in which 
H2As may have an odds ratio as low as 0.490 to one as high as 3.10.44 Further study may be 
required to further explore the complex relationship between CDI risk and H2A use. 
 In the YNHH cohort, there was a higher CDI risk among the piperacillin/tazobactam 
group than in the ceftazidime group as shown in Figure 2. Since this difference was supported by 
statistical significance, it results in a rejection of the null hypothesis that penicillin and 
cephalosporin drugs are associated with an equivalent CDI risk.  
 As displayed in Table 5, patients in the YNHH piperacillin/tazobactam cohort receiving 
H2A therapy (in addition to piperacillin/tazobactam therapy) had 0.497 times the odds of 
developing CDI as compared to patients who were not receiving H2A therapy. Similar to the 
findings in Table 3, this further falls in line with inconsistent data surrounding H2A use and CDI 
risk. Further study may be needed to evaluate H2A therapy based on distribution of its use. 
Patients in the piperacillin/tazobactam group with higher Charlson comorbidity index scores 
were found to have lower odds of developing CDI than patients with lower scores. Contrasting 
with findings in Table 3, it is possible that other covariates may have played a more significant 
role in confounding CDI risk associated with piperacillin/tazobactam therapy at YNHH. The 
odds ratio of 0.855 is not significantly lower than the 1.0 mark, so it is possible that other 
variables may have played a more significant role in confounding CDI risk. Another reason to 
suggest additional confounding is the findings’ contrast with existing literature regarding the 
direct association between Charlson comorbidity index scores and CDI risk. A longer duration of 
hospital admission was found to have an almost negligible increase in CDI risk as well. 
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 Patients of an older age and increased duration of hospital admission in the YNHH 
ceftazidime group had a slightly higher odds of developing CDI as shown in Table 6. Older age 
may increase CDI risk due to age-related impairment of the immune system, higher antibiotic 
utilization, and more frequent healthcare exposure.45,46 However, some studies also indicate a 
small magnitude of the documented risk, which is demonstrated by the odds ratio of 1.045 in 
Table 6.47 PPI use in the YNHH ceftazidime was conversely shown to have a low odds ratio of 
0.253 with regards to CDI risk (Table 6). Although the confidence interval had a wide range, this 
finding contrasts current literature depicting the association between PPI use and CDI risk. 
Consistent with the proposed mechanisms for H2A use being associated with a higher CDI risk, 
the stomach acid suppression induced by PPI use has been shown to introduce environmental 
conditions favorable for C. difficile proliferation.48 Many studies demonstrate a relatively high 
risk of acquiring principal and recurrent CDI following prolonged PPI use.49 Several studies have 
shown odds ratios ranging from 0.8 to 18.1 with regards to developing CDI.50 There are some 
contrasting studies showing lower corresponding odds ratios ranging from 0.4 to 0.8.48 Further 
study may be required to evaluate the other binary covariates to more closely examine the 
association with PPI use. Another potential hypothesis to explain the documented low odds of 
CDI risk associated with PPI use is a distribution of days of therapy and distribution of use. It is 
possible that due to the strong acid suppression capabilities of PPIs, they are used in more 
critically ill patient populations such as those admitted to intensive care units. A closer 
examination may focus on the distribution of PPI use by hospital site or days of therapy to better 
assess severity of acute disease. These analyses may further explain the depicted inverse 
association between PPI use and CDI risk. 
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 The higher CDI risk associated with piperacillin/tazobactam at YNHH brings about 
questions of imposing any restrictions on the formulary. As this study has shown a higher CDI 
risk associated with its empiric prescription, the two key remaining factors to consider are risk 
factors for HAIs and the cost. As stated in the literature, piperacillin/tazobactam has excellent 
coverage against Gram-positive, Gram-negative, and anaerobic bacteria. Ceftazidime is primarily 
reserved for use against Gram-negative bacteria such as Pseudomonas aeruginosa.31 One study 
directly compared the use of piperacillin/tazobactam and broad-spectrum cephalosporins with 
evaluating the risk for HAIs caused by drug-resistant Enterobacter spp., in which cephalosporin 
therapy led to a higher risk of infection.51 Another study determined that piperacillin/tazobactam 
and broad-spectrum cephalosporins were associated with similar CDI risks for developing intra-
abdominal infections, bloodstream infections, and urinary tract infections caused by Gram-
negative bacteria.52 While the costs and risk for HAIs caused by Gram-negative bacteria are 
similar between both antibiotics, the factor that may recommend against a YNHH formulary 
change is piperacillin/tazobactam’s extended coverage against common Gram-positive and 
anaerobic bacteria which may be needed in some clinical circumstances.  
 Although no difference in CDI risk between piperacillin/tazobactam and cefepime was 
observed in the BH cohort, cefepime and ceftazidime share structural and procedural similarities 
as they are both β-lactam antibiotics in the cephalosporin class. Furthermore, there is some 
evidence showing provider preference for cefepime over ceftazidime as anti-pseudomonal 
agents.53 Some data supports this assertion by showing lower drug resistance among pneumonia 
patients and less incident vancomycin-resistant Enterococcus (VRE) among cefepime treatment 
groups compared to those with ceftazidime.54 However, clinical outcomes for pneumonia did not 
considerably differ between the cefepime and ceftazidime treatment groups in the study.54 
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Cefepime’s added Gram-positive coverage may warrant additional study to compare the CDI risk 
between penicillin and cephalosporin drugs. The current findings may indicate that cefepime has 
a similar impact on altering the commensal gut flora as piperacillin/tazobactam, accounting for a 
similar CDI risk. In the YNHH cohort, the findings indicate that ceftazidime may not 
significantly alter the composition of the commensal gut flora, explaining the lower CDI risk. 
Despite a recommendation against a formulary change at YNHH, the discrepancy in CDI risk 
between piperacillin/tazobactam and ceftazidime may justify further action given the rising trend 
of CDI incidence. The observed discrepancy may lead to further investigation into the possibility 
of favoring ceftazidime for empiric Gram-negative coverage when Gram-positive and anaerobic 
coverage are not warranted.  
 An alternative explanation to address the discrepancy in CDI risk between 
piperacillin/tazobactam and ceftazidime may be attributed to an inherently higher overall degree 
of utilization of piperacillin/tazobactam relative to ceftazidime.55 Due to its broader coverage, 
utilization of piperacillin/tazobactam is significantly higher and can span a wider patient 
population including multiple subsets with higher risks for developing CDI. 
 One study measured trends in antibiotic use among an alliance of US hospitals between 
2002 and 2006, in which the researchers found an 84% increase in piperacillin/tazobactam over 
the 5-year study period.56 This significant increase occurred despite sporadic national 
piperacillin/tazobactam shortages, indicating that the rate of increase could potentially accelerate 
as the shortage alleviated. During this study period, piperacillin/tazobactam was the third most 
commonly prescribed antibiotic within the focused network of hospitals behind vancomycin and 
cefazolin.56 As the rate of prescribing has increased in recent years, additional studies evaluate 
appropriate use of the antibiotic based on empiric indication. Two studies conducted such an 
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evaluation, in which one study determined that piperacillin/tazobactam was used 
“inappropriately” 17% of the time compared to 7% of the time for vancomycin. Another study 
determined that in four hospitals, piperacillin/tazobactam was inappropriately used 28.5% of the 
time.57,58 In this study, piperacillin/tazobactam utilization may have differed by hospital to 
explain the observed discrepancies. 
The YNHH piperacillin/tazobactam group was also tested for CDI more frequently than 
the YNHH ceftazidime group. One potential explanation for this finding is that 
piperacillin/tazobactam may have been prescribed more frequently in critical care patients 
compared to ceftazidime. As a result, patients prescribed piperacillin/tazobactam may have had 
an inherently higher risk for developing CDI, leading to more frequent testing and more positive 
CDI cases. It is possible that the positive results in the YNHH piperacillin/tazobactam group may 
be reflective of C. difficile colonization rather than true infection. Colonization is either 
symptomatic or asymptomatic. Symptomatic colonization is associated with signs of diarrhea, 
whereas asymptomatic colonization is the detection of C. difficile in the absence of diarrhea.59 If 
the positive test results reflected colonization, this may not support the assertion that 
piperacillin/tazobactam is necessarily associated with its depicted risk. Some studies have shown 
that 1-4% of healthcare workers in the US may be asymptomatically colonized with C. difficile, 
whereas 7-15% of non-healthcare workers outside the US may be asymptomatically colonized 
with C. difficile.60,61  
A potential implication of the more frequent testing among the YNHH 
piperacillin/tazobactam group may indicate that piperacillin/tazobactam poses a greater risk for 
antibiotic-associated diarrhea. Diarrhea is a common adverse event associated with antibiotic 
therapy. One study shows that antibiotic-associated diarrhea occurs in 5-30% of patients either 
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shortly after initiating antibiotic therapy or up to two months following the conclusion of 
treatment.62 While there is variation in the prevalence of antibiotic-associated diarrhea with 
different antibiotic classes, current literature has shown significant associations between 
antibiotic-associated diarrhea and piperacillin/tazobactam therapy.63,64 This potential link may 
distinguish between the risk of C. difficile colonization or true infection associated with 
piperacillin/tazobactam. C. difficile is known to be a major contributor to antibiotic-associated 
diarrhea, in which 10-25% of antibiotic-associated diarrhea cases are attributed to the anaerobic 
bacterium.62 Future study may explore this distribution of penicillin and cephalosporin drugs by 
site of care to lend an explanation for the differences in C. difficile testing patterns. As such 
discrepancies in antibiotic utilization are observed, the focus shifts to optimal antibiotic 
stewardship. 
Several strategies have been implemented to de-escalate antibiotic use including 
bolstering facility-wide educational programs and setting new standards for selection of an 
appropriate agent, route of administration, dose, and duration of therapy.65 One strategy used to 
combat high utilization of antibiotics is the implementation of a “time-out”3 in a hospital’s 
electronic medical record.66 A team at a tertiary care hospital implemented a 72-hour time-out 
for piperacillin/tazobactam, which involved installing a “stop” in the electronic medical system 
for empiric piperacillin/tazobactam orders for patients lacking positive cultures. The team noted 
a significant decrease in the duration of empiric use, inappropriate dosing, and an increase in the 
rate of antibiotic de-escalation.67 In the case that higher piperacillin/tazobactam utilization 
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contributed to the difference in CDI risk compared to ceftazidime, it may warrant further 
exploration into antibiotic de-escalation interventions.  
Alternatively, one tertiary care hospital implemented an antibiotic stewardship program 
aiming to decrease overall cephalosporin use in terms of recommended daily doses (RDD) per 
100 patient days.68 While third-generation cephalosporin use decreased from 16.3 RDD per 100 
patient days to 10.3 RDD per 100 patient days, it also led to penicillin use increasing from 15.4 
RDD per 100 patient days to 18.2 RDD per 100 patient days.68 Another study followed a similar 
antibiotic stewardship program structure and observed an overall decrease in third-generation 
cephalosporin use from 34 RDD per 100 patient days to 11 RDD per 100 patient days.69 The 
program also led to a ten-fold increase in penicillin use.69 While current literature postulates that 
penicillin drugs may be preferable with regard to lowering CDI risk compared to cephalosporin 
drugs, the impact of cephalosporin de-escalation may also increase penicillin utilization to the 
point of potentially raising CDI risk. Along with a closer examination for piperacillin/tazobactam 
de-escalation in particular clinical situations, it may be worthwhile to perform a similar 
examination for cephalosporin de-escalation. Further study may explore the relationship between 
the utilization of cephalosporin drugs and penicillin drugs, particularly following the 
implementation of an antibiotic stewardship program focusing on either antibiotic class. To work 
towards achieving optimal antibiotic stewardship, the associated costs with each antibiotic class 
may also be an area of additional study, as utilization of some antibiotic classes have been shown 
to incur higher costs than that of others.70 
 Optimal antibiotic stewardship requires efforts in both the hospital and community. CDC 
analysis revealed a slight downwards trend in outpatient antibiotic prescribing from 877 
prescriptions per 1,000 persons in 2010 to 835 prescriptions per 1,000 persons in 2014.71 
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However, this rate slightly increased in 2015 to 838 prescriptions per 1,000 persons in 2015.71 
While this increase may be viewed as minor, researchers found that at least 30% of the included 
outpatient antibiotic prescriptions were deemed “unnecessary”. This shift is noticeably worse 
among the elderly population, who concurrently are at a higher risk for CDI than the younger 
demographic. Following a similar trend as in the CDC analysis, a team of researchers measured a 
steady decline in outpatient antibiotic prescriptions in the elderly from 1,364 claims per 1,000 
beneficiaries in 2010 to 1,309 claims per 1,000 beneficiaries in 2014.72 This rate, however, rose 
to 1,364 claims per 1,000 beneficiaries in 2015. Current literature has shown an increase in 
incident CDI in the community, in part due to excessive antibiotic use in the outpatient setting. 
While the interaction between CA-CDI and HA-CDI is not fully understood, many researchers 
agree on the presence of an association to some degree.73,74 As more individuals are hospitalized 
due to CDI, the likelihood of shedding the pathogen into the hospital environment increases. 
While reducing CDI incidence requires a litany of interventions spanning hand hygiene, 
environmental cleaning, and diagnostic stewardship, antibiotic stewardship addresses the 
principal risk factor for CDI cases.  
This study has several limitations. First, no inter-facility or aggregate 
(piperacillin/tazobactam versus third/fourth-generation cephalosporin) comparison was made 
between BH and YNHH to evaluate comparative CDI risk associated with empiric antibiotic 
therapy. This was primarily due to the differing C. difficile assays used at each hospital (See 
Appendix 2), variation in provider preferences, and subsequent complexities with assay 
standardization. An inter-facility comparison may provide more robust clinical data to support 
any decisions concerning a change to the existing formulary. Further study may revolve around 
such an aggregate comparison due to similarities in the patient populations at BH and YNHH.  
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Second, the composition of inpatients has shifted over the 5-year study duration at BH 
and YNHH. Due to the exclusion criteria by inpatient unit, it is possible that eligible patients 
such as those in general medicine were excluded as a result of being admitted to an excluded 
unit. Conversely, it is possible that ineligible patients such as those in hematology-oncology 
were included due to being admitted to a general medicine unit.  
Third, patients were included based on the first hospital admission falling under the 
inclusion criteria. Many patients had multiple hospital admissions in which there was a 
possibility of a CDI diagnosis in a subsequent hospitalization. However, since all patient data 
from the first eligible admission was used, some CDI cases may have been missed despite 
potentially being linked to antibiotic use.  
Fourth, the antibiotic confounders were restricted to select antibiotics known to be high-
risk. Based on current literature, cephalosporins, clindamycin, fluoroquinolones, and 
carbapenems have been associated with high CDI risk. Specific antibiotics were included based 
on the drugs available on the BH and YNHH formularies. While most studies conclude that there 
is a low CDI risk associated with tetracyclines, some show a moderate CDI risk associated with 
additional penicillin drugs and macrolides.25,26 In some cases, macrolides have shown to have an 
odds ratio of 5.2 of developing CDI with the BI/NAP1/027 strain and a relative risk of 1.30 when 
evaluating patients with penicillin allergies.75,76,77 The BI/NAP1/027 strain, first isolated in North 
America, has gained attention due to its propensity to cause severe outbreaks with unexpectedly 
high mortality.77 Due to the significantly high virulence, it has been hypothesized that the 
BI/NAP1/027 strain may be associated with additional or different risk factors commonly 
associated with other strains.77 As a result, macrolides and other moderate-risk antibiotics 
become of more importance when evaluating CDI risk with antibiotic use for more novel strains. 
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Although the data evaluating CDI risk with macrolide therapy is inconsistent, this category was 
excluded from the high-risk classification. One cannot rule out its status as a confounder, 
particularly if it is preferred for a patient population with allergies to penicillin drugs such as 
piperacillin/tazobactam. 
Fifth, Charlson comorbidity index scores were solely available at the time of patient 
discharge. As a Charlson comorbidity index score may change throughout a patient’s visit, the 
recorded scores may be higher or lower than that present upon admission. Additionally, these 
scores measure the likelihood of a patient’s death over the course of the next six months; they do 
not measure the acute severity of disease. Although Charlson comorbidity index scores were 
reported to be similar across the studied cohorts, they do not measure severity of disease which 
may have explained discrepancies in C. difficile testing patterns. 
 Next steps will focus on evaluating an aggregate comparison of CDI risk between 
piperacillin/tazobactam and third/fourth-generation cephalosporin drugs. A statistical consult 
may be sought for optimal standardization of facility-level differences (provider preference, 
patient demographics, C. difficile testing patterns) between both hospitals. These aggregate 
findings may shed more insight into comparative CDI risk between antibiotics and explain the 
discrepancies in associated CDI risk observed in both hospitals studied.  
Another next step may be a deeper level of analysis evaluating the impact of covariates 
such as PPI and H2A use on CDI risk. Due to the fact that some continuous covariates are not 
normally distributed, stratification or categorization may be needed for a more robust mode of 
confounding analysis. An example of further risk stratification could be examining 
piperacillin/tazobactam, cefepime, or ceftazidime therapy by site of care to address potential 
confounding with their distributions of use. Addressing existing limitations such as parsing out 
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those who received empiric antibiotic therapy following a C. difficile test may be a priority. 
Primary exposure variables such as days of therapy can be further broken down into categories to 
allow for a closer look on the specific time point(s) in which the CDI risk of one antibiotic began 
separating from that of the other. Another possibility is to incorporate other modes of bivariate 
and multivariate analysis to further explore the complex relationships between CDI risk and the 
individual covariates.  
 Overall, the relationships between CDI risk and empiric antibiotic use in this study reflect 
the variation observed in current literature. Piperacillin/tazobactam at YNHH was shown to have 
a higher CDI risk than ceftazidime, whereas no difference in CDI risk between 
piperacillin/tazobactam and cefepime at BH was observed. These results contrasted the 
hypotheses based on existing literature, warranting a closer look in sources of variation in CDI 
risk between the antibiotics in question. Additional study may be needed to further stratify the 
CDI risk associated with individual antibiotics within a class and explore various interventions to 
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Appendix 
 
Appendix 1: CDC NHSN LabID for Clostridioides difficile 
 
According to The Centers for Disease Control and Prevention, an individual must meet at least 
one of the following criteria to be infected with C. difficile: 
 
1) Positive test for toxin-producing C. difficile on an unformed stool specimen (conforms to the 
shape of the container). 
 
2) Patient has evidence of pseudomembranous colitis on gross anatomic (includes endoscopic 
exams) or histopathologic exam. 
 
Appendix 2: C. difficile assays for BH and YNHH 
 
Bridgeport Hospital Testing Algorithm: 
 
If GDH/Rapid Toxin assay result: Negative/Negative → No CDI 
If GDH/Rapid Toxin assay result: Positive/Positive → CDI present 
If GDH/Rapid Toxin assay result: Discordant → PCR required 
 If PCR result: Positive → CDI present 
 If PCR result: Negative → No CDI 
 
YNHH Testing Algorithm: 
 
If GDH/Rapid Toxin assay result: Negative/Negative → No CDI 
If GDH/Rapid Toxin assay result: Positive/Positive → CDI present 
If GDH/Rapid Toxin assay result: Discordant → Cytotoxin Neutralization Assay required 
 If Cytotoxin Neutralization Assay result: Positive → CDI present 
 If Cytotoxin Neutralization Assay result: Negative → No CDI 
 
